Global Insulin Pump Market Size
The insulin pump market is expected to be worth around US$ 11.12 billion by 2032, compared to US$ 4.63 billion in 2023. The CAGR for the Insulin Pump Industry from 2024 to 2032 is 10.23%.
The technology for insulin pumps is rapidly evolving. An insulin pump is a wearable medical device that supplies a continuous flow of rapid-acting insulin underneath your skin. Most pumps are small, computerized devices roughly the size of a juice box or a deck of cards. Insulin pumps are an alternative to multiple daily injection (MDI) insulin therapy (syringe or pen injections) for people with diabetes who require insulin to manage the condition.
Request a free sample copy of the report: https://www.renub.com/insulin-pump-market-and-forecast-worldwide-analysis-127-p.php
The insulin pump market is a critical segment within the broader diabetes management industry, reflecting significant advancements in medical technology to improve the quality of life for individuals with diabetes. Valued at approximately $6 billion in 2023, the market is poised for substantial growth, driven by the rising prevalence of diabetes, increasing awareness of diabetes management options, and continuous technological innovations.
Insulin pumps are devices used to deliver continuous subcutaneous insulin infusions (CSII) to individuals with diabetes. They provide a more flexible and precise method of insulin administration compared to traditional injection techniques. These pumps are particularly beneficial for patients with type 1 diabetes, although they are also increasingly used by individuals with type 2 diabetes who require intensive insulin therapy.
Several key factors are driving the growth of the insulin pump market. The increasing global incidence of diabetes is a primary driver, with the International Diabetes Federation reporting over 460 million people living with diabetes worldwide. This growing patient population necessitates effective and convenient management solutions, spurring demand for insulin pumps.
Technological advancements play a significant role in market expansion. Modern insulin pumps are becoming more sophisticated, incorporating continuous glucose monitoring (CGM) integration, automated insulin delivery systems (AID), and wireless connectivity. These features enhance the accuracy of insulin delivery, reduce the risk of hypoglycemia, and provide real-time data to patients and healthcare providers. Companies like Medtronic, Insulet, and Tandem Diabetes Care are at the forefront of these innovations, continually improving pump functionality and usability.
Another crucial factor is the increasing awareness and education regarding diabetes management. Healthcare providers and diabetes educators play a vital role in informing patients about the benefits of insulin pump therapy, leading to higher adoption rates. Additionally, various health organizations and government initiatives support diabetes management programs, further boosting market growth.
The market also benefits from favorable reimbursement policies in many developed countries, making insulin pump therapy more accessible to patients. However, high costs and limited access in developing regions pose challenges to market penetration.
India Insulin Pump Market
According to a government study from 2023, 11% of India’s population, which is 101 million people, has diabetes. The India Insulin Pumps Market is highly competitive, with numerous international and domestic players vying for market share. Significant factors driving growth in the Indian insulin pump market include the increasing prevalence of diabetes in the country and growing awareness of insulin pump therapy’s benefits among patients and healthcare professionals. Insulin pumps offer several advantages over traditional insulin injection therapy, including more precise dosing and the ability to continuously monitor blood glucose levels. As awareness of these benefits increases, more patients are expected to adopt insulin pump therapy. Studies show that the incidence of type 1 diabetes is increasing at a rate of approximately 3–5% per year. Although Type 1 diabetes is mainly hereditary, it can also be triggered by an autoimmune response to viruses or the environment. Additionally, insulin pumps are commonly used by people diagnosed with type 2 diabetes in India.
In March 2022, Medtronic India introduced the MiniMed 780G, a closed-loop insulin pump system for individuals with type 1 diabetes. In 2023, Pfizer acquired Seagen for approximately US$43 billion, marking the largest biopharma M&A deal.
Insulin Pump Market Company Analysis
Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche, Insulet Corp., Ypsomed Holding AG, and Microtech Medical are critical businesses in the global insulin pump market.
Insulin Pump Market Company News
- In January 2024, Abbott and Tandem Diabetes Care, Inc. revealed that the t-slim X2 insulin pump featuring Control-IQ technology is the inaugural automated insulin delivery (AID) system to incorporate the recently launched FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) innovation.
- In January 2023, Tandem Diabetes Care finalized its acquisition of AMF Medical, the maker of the Sigi patch pump for insulin delivery. Despite Tandem’s plans to acquire AMF Medical, the Switzerland-based company does not offer Sigi commercially. Notably, the Sigi system received FDA breakthrough device designation over a year ago.
- In February 2023, Insulet Corporation, known for its Omnipod® brand of products, acquired assets related to Bigfoot Biomedical’s pump-based automated insulin delivery (AID) technologies.
- In November 2023, ViCentra B.V., the company behind Kaleido, unveiled a hybrid closed-loop system for automated insulin delivery in partnership with Diabeloop DBLG1 control software and the Dexcom G6 CGM sensor. This advanced system improves users’ time-in-range glucose values by 16.7%.
Types – Market breakup in 3 viewpoints:
1. Tethered Pumps
2. Patch Pumps
3. Consumables
Diseases – Market breakup in 2 viewpoints:
1. Type 1 Diabetes
2. Type 2 Diabetes
Accessories – Market breakup in 3 viewpoints:
1. Action Figures Insulin Reservoirs
2. Infusion Sets
3. Infusion Set Insertion Devices
End-user – Market breakup in 3 viewpoints:
1. Action Figures Hospital and Clinics
2. Home Care
3. Others
Countries – Market breakup of 25 Countries:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis
Company Analysis:
1. Medtronic
2. Insulet Corporation
3. Tandem Diabetes Care
4. Roche
5. Insulet Corp.
6. Ypsomed Holding AG
7. Microtech Medical
Related Reports:
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Contact Us:
Renub Research
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: info@renub.com
LinkedIn: https://in.linkedin.com/company/renub-research
Website: https://www.renub.com/
Leave a Reply
You must be logged in to post a comment.